Table 1.

Patient Characteristics at Study Entry

Patient Number	Age (Y)—Sex (Female/Male)	Diagnosis	Ann Arbor Stage (SLL)/Modified Rai Stage (CLL)/Binet Stage (CLL)	CIRS-G Score (Miller and Towers 1991)	Cytogenetic Abnormalities (FISH)					TP53 Mutation Status (Yes/No)	IGHV Mutation Status (UM/M)	Hypogammaglobulinemia (Yes/No)	Prior Treatment Lines (n)
					trisomy 12 (Yes/No)	del(13q) (Yes/No)	del(17p) (Yes/No)	del(11q) (Yes/No)	Complex Karyotypea (Yes/No)
01	77—M	SLL	IV/−/−	6	No	Yes	No	Yes	No	No	Mb	No	1
02	57—M	CLL	−/high/C	0	No	Yes	No	Yes	No	No	UM	No	2
03	73—M	CLL	−/inter./B	8	No	Yes	Yes	No	No	No	M*	Yes	4
04	74—M	CLL	−/high/C	4	Yes	Yes	Yes	No	Yes	No	M	Yes	1
05	73—M	CLL	−/inter./B	3	No	Yes	Yes	No	No	No	M	N/A	1
06	75—F	CLL	−/high/C	0	No	Yes	Yes	No	No	Yes	M	Yes	2
07	64—M	CLL	−/high/C	4	No	Yes	Yes	No	No	No	UM	Yes	1
08	79—M	CLL	−/high/B	4	No	Yes	No	No	No	Yes	UM	N/A	2
09	52—M	CLL	−/high/C	0	No	Yes	Yes	No	No	N/A	N/A	YES	2
10	68—F	CLL	−/inter./B	3	No	Yes	Yes	No	No	N/A	N/A	YES	1
11	66—F	CLL	−/high/C	0	Yes	Yes	Yes	No	Yes	N/A	N/A	Yes	1

^aComplex karyotype was defined as the presence of ≥3 cytogenetic abnormalities as measured by FISH.

^bBorderline IGHV mutated (defined as 97%–98% sequence identity to germline).

CLL = chronic lymphocytic leukemia; CIRS-G = Cumulative Illness Rating Scale for Geriatrics; FISH = fluorescence in situ hybridization; IGHV = immunoglobulin heavy chain variable region; inter. = intermediate; M = mutated; N/A = not available; SLL = small lymphocytic lymphoma; UM = unmutated.